Swiss startup mimiX Biotherapeutics is revolutionizing the bioprinting skin product industry with a cutting-edge technology. FastSkin® tissue is an advanced dermal substitute for treating acute and chronic wounds, utilizing the unique biofabrication technique Sound Induced Morphogenesis (SIM).
SIM patterns biological materials like cells, organoids, or tissue fragments into 3D constructs for in vitro engineered tissues, enabling faster and more efficient multi-cellular assemblies. mimiX Biotherapeutics is seeking FDA clearance for FastSkin®, which could become the world's first acoustic cell patterning clinical product, marking a significant milestone for the industry.
Investment surge fuels MimiX Biotherapeutics' advancements in human tissue regeneration (venturelab.swiss)
Fresh capital brings Mimix a step closer to commercialization (startupticker.ch)
Venture Leaders Medtech soar high on Boston roadshow (venturelab.swiss)
Moving forward with experienced Board members (startupticker.ch)
MimiX Biotherapeutics: Meet the Venture Leader Medtech revolutionizing the bioprinting skin product industry (venturelab.swiss)
The Venture Leaders Medtech 2023 kick-off meeting sets the course for the Boston roadshow (venturelab.swiss)
Swiss Medtechs seek growth opportunities in Boston (startupticker.ch)
Venture Leaders Medtech 2023: 10 innovative startups will advance their global growth in Boston (venturelab.swiss)
Swiss startups prepare to visit the US East Coast (startupticker.ch)
Support from seasoned global industry leaders (startupticker.ch)
Mimix Biotherapeutics’ innovative skin graft a step closer to the market (startupticker.ch)